Moving Evidence into Practice: Breast Cancer Highlights From Chicago

This program will include a discussion of off-label treatment and investigational agents not approved by the Food and Drug Administration for use in the United States, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

I-SPY 2 Study

I-SPY 2 TRIAL Schema: HER2- Signatures

Pembrolizumab Graduated in All HER2- Signatures: Both HR+/HER2- and TNBC

Select Treatment-Related Adverse Events

AEs of Special Interest (Including Immune-Related Toxicities)

Primary and Secondary Adrenal Insufficiency

Conclusions

MONARCH 2 Phase 3 Trial

MONARCH 2 Results

Abemaciclib for Treatment of Brain Metastases

MONALEESA-2 Phase 3 Trial: Second Interim Analysis

PALOMA-1 Study

OlympiAD Trial

OlympiAD Trial: Results

Brightness Study

Brightness Efficacy Results

ABRAZO Phase 2 Clinical Trial: Key Eligibility Criteria

Primary Efficacy Endpoint: Talazoparib ORR by Independent Radiologist Facility

APHINITY Trial

APHINITY Results

Results of Subgroup Analysis of IDFS at 4 Years

Safety Profile

APT Trial

Updated Analysis of APT Trial

Abbreviations

Abbreviations (cont)